Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04971005
Other study ID # inims-009
Secondary ID
Status Terminated
Phase Phase 2
First received
Last updated
Start date August 27, 2021
Est. completion date February 4, 2022

Study information

Verified date March 2022
Source Universitätsklinikum Hamburg-Eppendorf
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A multicentre controlled phase II trial to compare the efficacy and safety of ocrelizumab or alemtuzumab and autologous Hematopoietic Stem Cell Transplantation (aHSCT). Active relapsing-remitting MS-Patients will be included and randomised to ocrelizumab or alemtuzumab versus aHSCT. Primary endpoint will be the time to treatment failure as assessed by failure of NEDA (no evidence of disease activity) as represented by: no expanded disability status scale (EDSS) progression, no relapse, no new T2 lesion and no Gd-enhancing lesion. This trial offers the opportunity to gain further information about efficacy and safety of all treatments and will give new insights into the immunology of highly active RRMS.


Description:

A rater-blinded multicentre randomised controlled phase II trial to compare the efficacy and safety of ocrelizumab or alemtuzumab and aHSCT. Active RRMS-Patients will be included and randomised to ocrelizumab or alemtuzumab versus aHSCT. Primary endpoint will be the time to treatment failure as assessed by failure of NEDA (no evidence of disease activity) as represented by: no expanded disability status scale (EDSS) progression, no relapse, no new T2 lesion and no Gd-enhancing lesion. aHSCT appears highly efficacious in reducing inflammatory disease activity and relapses in active relapsing-remitting MS. Cohort data show a long-term stagnation of inflammatory disease activity for up to 10 years and more after aHSCT. However, efficacy data from randomised controlled trials comparing aHSCT with approved treatments are still lacking. The best available data concerning disease activity in MS patients with a documented treatment failure are from the CARE-MS II trial. The rate of patients without clinical or radiological disease activity after 2 years was 32% with alemtuzumab. aHSCT trial data on absence of disease activity show NEDA rates between 70 and 90% after 2 years. Here we assume 40% and 80% after 2 years for the ocrelizumab/alemtuzumab and aHSCT groups, respectively. For all three treatments, a potential long-term benefit has to be balanced with potentially harmful treatment related risks. A randomised controlled trial offers the opportunity to gain further information about efficacy and safety of all treatments and will give new insights into the immunology of high active RRMS.


Recruitment information / eligibility

Status Terminated
Enrollment 1
Est. completion date February 4, 2022
Est. primary completion date February 4, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria (Based on CARE-MS-II3, guidelines and Rio-criteria for treatment failure): - Written informed consent and agreement to comply to study protocol - Age: 18-55 years - EDSS: 0.0 - 6.0 - RRMS according to McDonald 2010 - < 10 years of disease course after symptom onset - Active disease with one of the following treatment failures occur-ring not earlier than 6 months after initiation of an approved DMT - 2 or more relapses within the last 12 months or - 1 relapse within the last 12 months and a Gd-enhancing lesion on MRI > 3 mm > 3 months before or after relapse onset or 2 new T2-lesions or - On-going signs of MRI activity in the last 6 months (either Gd-en-hancing of = 3 mm lesion at any exam in the last year; or more than 5 new T2 lesions (= 3 mm) or - Patients stable under natalizumab but who have to stop treatment due to an increasing PML risk are defined as active, if a MRI within 6 months after termination of natalizumab shows new T2 or Gd-enhancing lesions and at least one other treatment fail-ure prior to natalizumab is documented. Exclusion Criteria: - Secondary or primary progressive MS - Pregnancy, or other medical condition incompatible with aHSCT - Any treatment or medical condition that, according to the haematologist / transplant specialist precludes the use of aHSCT - John Cunningham virus (JCV) antibody index of > 1.5 in previ-ously natalizumab-treated patients, if a negative CSF JCV-PCR prior to screening is not available - Relapse during 30 days before initiation of treatment. If a relapse occurs during this period and eligibility criteria are otherwise ful-filled, start of treatment will be delayed until at least 30 days after receiving steroids. - Concurrent clinically significant (as determined by the investiga-tors and haematologist / transplant specialist) cardiac, immuno-logical, pulmonary, neurological, renal or other major disease such as: - Prominent cardial disease (Left ventricular ejection frac-tion (LVEF) < 40%, myocardial infarction or ischemia, un-controlled arrhythmias, pericardial effusion > 1 cm) - Cerebrovascular disease - Renal disease (creatinine clearance < 30 ml/min/m2) - Respiratory disease (DLCO < 40% predicted) - Active bleeding or clotting disease - History of human immunodeficiency virus (HIV) or posi-tive HIV antibody testing - Any uncontrolled acute or chronic infection, including HIV, hepatitis B surface antigen positivity and hepatitis C PCR positivity - Cancer except in situ cervix or cutaneous - Unwillingness or inability to comply with the requirements of this protocol including the presence of any condition (physical, men-tal, or social) that is likely to affect the patient returning for follow-up visits on schedule. Unwillingness to use contraception. - Previous participation in this study, previous treatment with aHSCT or already both comparators - Ongoing immunotherapy. Treatment with interferon or glati-rameracetate will need no wash-out. Treatment pause before oc-relizumab/alemtuzumab or aHSCT will be: - for dimethylfumarate and fingolimod: 8 weeks - for natalizumab: 8 weeks - for ocrelizumab: 12 weeks - for alemtuzumab: 12 months - for teriflunomide: 4 weeks after elimination with cholesty-ramine - for cladribine: 24 weeks - Patients with cognitive impairments who are unable to provide written, informed consent prior to any testing under this protocol, including screening and baseline investigations that are not con-sidered part of routine patient care.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Autologous Hematopoietic Stem Cell Transplantation
Autologous Hematopoietic Stem Cell Transplantation
Ocrelizumab
600 mg every 6 months continuously
Alemtuzumab
12 mg/day for 5 consecutive days and again after 365 days for 3 days

Locations

Country Name City State
Germany Universitätsklinikum Hamburg-Eppendorf Hamburg
Germany Universitätsklinikum Mannheim Mannheim

Sponsors (3)

Lead Sponsor Collaborator
Universitätsklinikum Hamburg-Eppendorf Clinical Trial Center North (CTC North GmbH & Co. KG), Neovii Biotech

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Time to treatment failure as assessed by failure of NEDA (no evidence of disease activity) Time to treatment failure as assessed by failure of NEDA (no evidence of disease activity) during follow-up as defined by:
3 months confirmed EDSS (Expanded disability status scale) progression
confirmed relapse
new/enlarging T2-hyperintense lesion on MRI (Magnetic resonance imaging)
any Gd-enhancing lesion on MRI
through study completion, on average at least 2 years
Secondary Efficacy of treatment defined by EDSS EDSS change and EDSS improvement will be considered. EDSS improvement defined as confirmed improvement after 3 months through study completion, on average at least 2 years
Secondary Efficacy of treatment defined by the annualized relapse rate calculated as number of relapses per year through study completion, on average at least 2 years
Secondary Efficacy of treatment defined by the number of new T2 lesions calculated as cumulative number of new T2 lesions through study completion, on average at least 2 years
Secondary Efficacy of treatment defined by the number of Gd-enhancing lesions calculated as cumulative number of GD-enhancing lesions through study completion, on average at least 2 years
Secondary Efficacy of treatment defined by multiple sclerosis functional composite (MSFC) change based on summed up Z-scores for individual measures (SDMT, 9 HPT, 25 FWT) through study completion, on average at least 2 years
Secondary Efficacy of treatment defined by Hamburg quality of life scale in MS (HAQUAMS) based on HAQUAMS sum score ratings (values between 1 and 5) through study completion, on average at least 2 years
Secondary Efficacy of treatment defined by the Percentage Brain Volume Change (PBVC) Brain tissue volume (grey matter, white matter) will be evaluated on T1 weighted images to compute absolute percentage brain volume change through study completion, on average at least 2 years
Secondary Efficacy of treatment defined by grey and white matter atrophy based on grey and white matter volume change evaluated on T1 weighted images through study completion, on average at least 2 years
Secondary Rate of AE / SAE including NCI grade 3 and 4 non-haematological toxicities Safety of treatment defined by the rate of AE / SAE including NCI grade 3 and 4 non-haematological toxicities through study completion, on average at least 2 years
See also
  Status Clinical Trial Phase
Completed NCT02549703 - Mitochondrial Dysfunction and Disease Progression
Terminated NCT02222948 - Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis Phase 2
Completed NCT02293967 - Mass Balance Study of MT-1303 Phase 1
Terminated NCT01790269 - Monitoring Natural Killer Cells in Multiple Sclerosis Patients Treated With Fingolimod
Terminated NCT01701856 - Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis Phase 4
Completed NCT00525668 - Sunphenon Epigallocatechin-gallate (EGCg) in Relapsing-remitting Multiple Sclerosis (SuniMS Study) Phase 1/Phase 2
Terminated NCT00398528 - An fMRI Study of Treatment Optimization Comparing Two Disease Modifying Therapies Used to Treat Relapsing Remitting Multiple Sclerosis Phase 4
Completed NCT00315367 - A fMRI(Functional Magnetic Resonance Imaging) Research Study to Learn More About Multiple Sclerosis and Individuals Potentially Experiencing Memory Difficulties Phase 4
Terminated NCT04032171 - Study of Evobrutinib in Participants With RMS Phase 3
Completed NCT01930708 - A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes Phase 4
Completed NCT03000647 - Guided Versus Non-guided Pelvic Floor Exercises for Urinary Incontinence in Relapsing-Remitting Multiple Sclerosis N/A
Completed NCT02205489 - Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA Phase 4
Completed NCT02753088 - Efficacy and Safety of BCD-063 and Copaxone-Teva in Patients With Relapsing-Remitting Multiple Sclerosis Phase 3
Recruiting NCT01466114 - Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition Phase 2
Completed NCT01416155 - Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple Sclerosis Phase 2
Completed NCT01244139 - Safety Study of BIIB033 in Subjects With Multiple Sclerosis Phase 1
Completed NCT00559702 - Safety Study of Natalizumab to Treat Multiple Sclerosis (MS) Phase 1
Completed NCT00493116 - Is IFN-beta Treatment in MS Useful After a Washout Period in Patients With Neutralizing Antibodies to Interferon Beta Phase 4
Terminated NCT01706107 - Canadian Multicenter Observational Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants
Completed NCT01943526 - Ireland Natalizumab (TYSABRI) Observational Program